Investment Analysts’ Weekly Ratings Changes for Haleon (HLN)

Haleon (LON: HLN) has recently received a number of price target changes and ratings updates:

• 11/5/2025 – Haleon had its price target raised by analysts at Berenberg Bank from GBX 507 to GBX 517. They now have a “buy” rating on the stock.
• 11/3/2025 – Haleon had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a GBX 440 price target on the stock.
• 10/31/2025 – Haleon had its “underweight” rating reaffirmed by analysts at JPMorgan Chase & Co..
• 10/31/2025 – Haleon had its “sector perform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a GBX 370 price target on the stock.

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other.